Your trusted source for investing success

Tag: in vitro

DelMar Presents Positive Interim Results from VAL-083 Study in MGMT-unmethylated Recurrent GBM at The Society for NeuroOncology Annual Meeting

DelMar Presents Positive Interim Results from VAL-083 Study in MGMT-unmethylated Recurrent GBM at The Society for NeuroOncology Annual Meeting

DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new cancer therapies, today provided an overview of three scientific posters presented at the 22nd Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO) held on November 16-19, 2017 in San Francisco, CA.

DelMar

ChroMedX Announces Closing of Private Placement

ChroMedX Announces Closing of Private Placement

ChroMedX Corp. (CSE:CHX) (OTCQB: CHXIF) (FSE: EIY2) (the “Company”) is pleased to announce that it has closed a non-brokered private placement (the “Offering”) of 7,570,500 units (“Units”) at a price of $0.20 per Unit for aggregate gross proceeds of $1,514,100. Each Unit is comprised of one common share of the

DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Component of Combination Chemotherapy Regimens for the Treatment of Solid Tumors including Brain and Ovarian Cancer

DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Component of Combination Chemotherapy Regimens for the Treatment of Solid Tumors including Brain and Ovarian Cancer

DelMar Pharmaceuticals, Inc. (Nasdaq:DMPI) (“DelMar” and “the Company”), a biopharmaceutical company focused on the development of new cancer therapies, today announced the presentation of new data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics which was held October 26 -30, 2017 at the Pennsylvania Convention Center in

10 Top 3D Printing Companies

10 Top 3D Printing Companies

It’s expected that the 3D Printing market will be worth over $30 billion by 2022. Here, the Investing News Network looks at 10 of the big players in the industry.

Enter Your Log In Credentials
This setting should only be used on your home or work computer.

×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network

Send this to a friend

Hi,
I thought you might find this interesting:
DelMar Presents Positive Interim Results from VAL-083 Study in MGMT-unmethylated Recurrent GBM at The Society for NeuroOncology Annual Meeting

URL: https://investingnews.com/daily/life-science-investing/pharmaceutical-investing/delmar-presents-positive-interim-results-val-083-study-mgmt-unmethylated-recurrent-gbm-society-neurooncology-annual-meeting/